215 related articles for article (PubMed ID: 34704389)
1. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia.
Patel M; Bellanti F; Daryani NM; Noormohamed N; Hilbert DW; Young K; Kulkarni P; Copalu W; Gheyas F; Rizk ML
Clin Transl Sci; 2022 Feb; 15(2):396-408. PubMed ID: 34704389
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia.
Naik J; Dillon R; Massello M; Ralph L; Yang Z
J Comp Eff Res; 2023 Mar; 12(3):e220113. PubMed ID: 36688591
[No Abstract] [Full Text] [Related]
4. Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.
Roberts JA; Nicolau DP; Martin-Loeches I; Deryke CA; Losada MC; Du J; Patel M; Rizk ML; Paschke A; Chen LF
JAC Antimicrob Resist; 2023 Apr; 5(2):dlad011. PubMed ID: 36880088
[TBL] [Abstract][Full Text] [Related]
5. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
Kaye KS; Boucher HW; Brown ML; Aggrey A; Khan I; Joeng HK; Tipping RW; Du J; Young K; Butterton JR; Paschke A
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094127
[TBL] [Abstract][Full Text] [Related]
7. New evidence in severe pneumonia: imipenem/ cilastatin/relebactam.
Girón RM; Ibáñez A; Gómez-Punter RM; Alarcón T
Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):46-49. PubMed ID: 35488826
[TBL] [Abstract][Full Text] [Related]
8. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
Heo YA
Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
[TBL] [Abstract][Full Text] [Related]
10. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
[TBL] [Abstract][Full Text] [Related]
11. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Smith JR; Rybak JM; Claeys KC
Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
[TBL] [Abstract][Full Text] [Related]
12. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Feng HP; Patel YT; Zhang Z; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda C; Gao W
J Clin Pharmacol; 2023 Feb; 63(2):166-171. PubMed ID: 36046982
[TBL] [Abstract][Full Text] [Related]
13. Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.
Martin-Loeches I; Shorr AF; Kollef MH; Du J; Losada MC; Paschke A; DeRyke CA; Wong M; Jensen EH; Chen LF
Open Forum Infect Dis; 2023 Jun; 10(6):ofad225. PubMed ID: 37383243
[TBL] [Abstract][Full Text] [Related]
14. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
15. New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
O'Donnell JN; Lodise TP
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0025622. PubMed ID: 35727059
[TBL] [Abstract][Full Text] [Related]
16. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date.
Sellarès-Nadal J; Eremiev S; Burgos J; Almirante B
Expert Opin Pharmacother; 2021 Aug; 22(12):1521-1531. PubMed ID: 34120547
[No Abstract] [Full Text] [Related]
17. Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Shorr AF; Bruno CJ; Zhang Z; Jensen E; Gao W; Feng HP; Huntington JA; Yu B; Rhee EG; De Anda C; Basu S; Kollef MH
Crit Care; 2021 Oct; 25(1):354. PubMed ID: 34600585
[TBL] [Abstract][Full Text] [Related]
18. A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
Wang X; Liu N; Wei Y; Zhang S; Li H; Yan B; Patel M; Wang H; Boundy KE; Colon-Gonzalez F; Zang Y; Zhao X
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288637
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
[TBL] [Abstract][Full Text] [Related]
20. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.
Bhagunde P; Colon-Gonzalez F; Liu Y; Wu J; Xu SS; Garrett G; Jumes P; Lasseter K; Marbury T; Rizk ML; Lala M; Rhee EG; Butterton JR; Boundy K
Br J Clin Pharmacol; 2020 May; 86(5):944-957. PubMed ID: 31856304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
